Introduction {#S1}
============

Tendons are dense connective tissues, which are critical for the integrity and function of our musculoskeletal system ([@B35]; [@B11]; [@B6]). Tendons are hierarchically organized and have an extracellular matrix (ECM) consisting mainly of collagen type I and a smaller portion of other collagens and proteoglycans ([@B49]). After injury, tendons need a long period for rehabilitation, especially in aged patients, accompanied with higher failure risk and unsatisfactory repair outcomes ([@B19]). Tissue aging involves many intrinsic and extrinsic processes and it is frequently linked with tissue degeneration, tendon rupture incidence as well as reduced healing capacity ([@B14]; [@B36]; [@B41]). In general, aging is reflected by a decline in organ and tissue homeostasis ([@B9]). Many studies on age-related diseases have revealed that a diminished stem cell pool is responsible for adult tissue degeneration ([@B54]). However, the exact molecular mechanism behind tendon aging and degeneration remain by large unclear.

By carrying out a direct comparison between TSPCs derived from young/healthy (Y-TSPC) and aged/degenerative (A-TSPC) Achilles tendons, we have reported that A-TSPCs exhibit in two dimensional (2D) culture profound phenotypic changes with a decline in multiple cellular functions ([@B23]). Moreover, microarray analysis showed a distinct transciptomal shift mRNA in A-TSPCs, namely, genes related to cell-cell and cell-matrix contacts, cytoskeleton and cell motility were significantly dysregulated ([@B23]). F-actin imaging as well as quantitative kinetic analysis of cytoskeleton turnover, demonstrated that A-TSPCs have accumulation of robust actin stress fiber with slow turnover that correlated with the significantly reduced migratory and *in vitro* would healing potential of these cells ([@B23]).

Self-assembled three-dimensional (3D) organoids, whereby cells form connections naturally between each other and to the deposited ECM, are considered as a promising culture models to investigate tissue formation *in vitro*. One widely used scaffold-free approach is the cell pellet model for *in vitro* chondrogenesis. For tenogenesis, more a tube-like cell sheet, composed of a multi-layered cellular architecture and ECM-rich patches, can be fabricated *in vitro* ([@B28]). These organoids maintain natural microenvironment and own autocrine and paracrine signaling pathways. Our recent results on 3D cell sheets formed by mesenchymal stem cells and TSPCs provided evidences for the suitability of this model to study *in vitro* tenogenic differentiation ([@B20]).

Thus, in this study we hypothesized that A-TSPCs will exhibit significant differences to Y-TSPCs in their potential to form 3D tendon organoids and our aims were first, to characterize the quality of the tendon sheets and second to outline dominant cellular and molecular traits underlying the expected A-TSPC phenotype.

Materials and Methods {#S2}
=====================

Cell Culture {#S2.SS1}
------------

Primary Y-TSPCs (*n* = 4) and A-TSPCs (*n* = 9) were collected from human non-injured Achilles tendon biopsies with an average age of 28 ± 5 years and 61 ± 13 years, respectively, and extensively validated and characterized in 2D culture ([@B23]; [@B30]) (Ethical Grant No. 166-08 of the Medical Faculty of the Ludwig-Maximilians-University, Munich). Details on donor cohort demographics, clinical indications, histological examination, inclusion and exclusion criteria are published in the [Supplementary Information](#SM1){ref-type="supplementary-material"} of [@B23]. In short, The Y-TSPC cohort was limited to only *n* = 4 due to the rarity of such clinical samples. The donors for the A-TSPC cohort were validated for degenerative status by histological examination. For extraction and purification of the cells, the tendon tissue was minced into small pieces, digested with 0.15% collagenase II (Worthington, Lakewood, NJ, United States) enzymatically in culture medium at 37°C overnight, then filtered with sterile nylon mesh (100 μm pore size), and centrifuged at 500 *g* for 10 min. No enrichment step was implemented. Afterward, the pelleted cells were resuspended and expanded in DMEM/Ham's F-12 medium with glutamine (365.3 mg/L), 1 × MEM amino acids, 10% FBS and 1% [L]{.smallcaps}-ascorbic acid-2-phosphate. Stem/progenitor character of the cells was verified in [@B23] by FACS and immunohistochemistry for MSC-related markers positive markers CD44, CD73, CD90, CD105, CD146 (pericyte marker), Musashi-1 and STRO-1 as well as negative markers CD19, CD34, CD45, HLA-DR) revealing a very homogeneous populations. Tendon-related genes such as the transcription factors Scleraxis, Eya1, and Six1, the tendon marker gene tenomodulin and several ECM proteins abundant in tendon (collagen types I and III, COMP, decorin, and tenascin C) were validated ([@B23]). Self-renewal and tri-lineage differentiation assays were also carried ([@B23]). For passaging, 60% confluent cells were detached by trypsin. Cells were used in the study at passage 2--6.

Cell Sheet Formation {#S2.SS2}
--------------------

The cell sheet protocol, depicted in [Figure 1A](#F1){ref-type="fig"}, comprises of a three-step procedure: expansion, stimulation and maturation ([@B20]). The three-step procedure is required for the self-assembly process of the cell sheet with (1) expansion -- formation of confluent cell layer; (2) stimulation - for apical deposition of ECM and enrichment cell-ECM interactions (glucose for energy supply, and ascorbic acid to serve as anti-oxidant and co-factor for collagen synthesis); and (3) maturation - by tendon specific ECM production and organization in the 3D space (TGF- β3 mediated signaling is critical for tenogenesis ([@B18], [@B17]). In the expansion step, both cell types (8 × 10^3^ cells/cm^2^) were cultured in 10 cm^2^ cell culture dishes (Falcon, New York, United States) until reaching full confluence in the basic medium. In the stimulation step, cells were supplemented with high glucose DMEM containing 10% FBS and 50 μg/mL ascorbic acid for 14 (Y-TSPCs) or 16.5 days (A-TSPCs). Afterwards, the continuous cell monolayers were detached manually with a cell scraper, rolled into a 3D tube-like cell sheet, stretched 10% manually and fixed with small pins in non-adhesive culture dish (Corning, New York, United States). In the last maturation step, all formed cell sheets were cultured for 14 days in maturation media containing high glucose DMEM with 10 ng/ml TGF-β3 and 50 μg/mL ascorbic acid.

![Cell sheet procedure and gross morphological data. **(A)** Cartoon depicting the 3-step protocol for cell sheet formation. **(B)** Representative macroscopy images Y-TSPC and A-TSPC sheets at day 14. **(C)** Success rate of all donors (upper panel) success rate of each individual donor (lower panel). **(D)** Comparison of TSPC sheet wet weight at day 1 and 14. **(E)** Comparison of TSPC sheet diameter at day 1 and 14. Y-TSPC *n* = 4; A-TSPC *n* = 9; \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001.](fbioe-08-00406-g001){#F1}

Cell Sheet Wet Weight and Diameter Analysis {#S2.SS3}
-------------------------------------------

Cell sheets wet weight and diameter were measured at day 1 and day 14 of the maturation step. For diameter evaluation, following algorithm was applied: (1) 5--8 sheets/donor were imaged; (2) 6 images/sheet were implemented; 5 diameters/image were measured manually and the mean was calculated; (3) the diameter of each sheet was analyzed as the mean from 6 images; (4) the diameter for each donor was expressed as mean diameter of 5--8 sheets. 4 Y-TSPC cell sheet and 9 A-TSPC cell sheet donors were applied. The quantitative data was processed with GraphPad Prism v.5 software (GraphPad software, CA, United States).

Cell Sheet Fixation and Cryo Cutting {#S2.SS4}
------------------------------------

Y-TSPC (*n* = 4 donors) and A-TSPC (*n* = 6 donors) cell sheets (2 sheets/donor) were fixed with 4% paraformaldehyde, cryoprotected with 10, 20, 30% sucrose/phosphate-buffered saline (PBS) gradient (Sigma-Aldrich Corporation, St Louis, United States) and embedded in Tissue-Tek (Sakura Finetek, Alphen aan den Rijn, Netherlands). Cryosections (10 μm thick) were collected with cryotome (Leica, Wetzlar, Germany), and stored until use at −20°C. Prior to staining, sections were equilibrated at room temperature and rehydrated with PBS for 5 min.

H&E (Hematoxylin and Eosin) Staining and Nuclear Angle Deviation Analysis {#S2.SS5}
-------------------------------------------------------------------------

4 Y-TSPC (*n* = 4 donors) and 6 A-TSPC (*n* = 6 donors), the sheets (1 sheet/donor) were placed in Hematoxylin solution for 3 min, rinsed with 0.1% HCl in PBS for dedifferentiation, washed in tap water for 5 min, immersed in Eosin solution for 3 min (both from Carl Roth, Karlsruhe, Baden-Württemberg, Germany), rinsed with distilled water for 30 s and covered with Depex (Serva, Heidelberg, Germany). H&E staining images were made with Nikon digital sight DS-U camera mounted at Nikon eclipse TE2000-U microscope (Nikon, Tokyo, Japan) and used for analysis of nuclear angular deviation. Since healthy resident cells in tendon tissue are well aligned to the tensile axis (muscle to bone), this parameter is useful to assess the quality of the 3D sheet organization, and the lesser the deviation the better the alignment. The following algorithm was implemented: (1) 9 images at x20 magnification were taken randomly from each cell sheet; (2) 9 randomly chosen nuclei per image were assessed (81 nuclei/sheet); (3) the angles between the longitudinal axis of the cell sheet and the long axis of the nuclei were determined with the "angular" tool of the AxioVision software v 4.8 (Carl Zeiss, Jena, Germany); (4) 324 and 486 angles for Y- and A-TSPC cohorts were analyzed, respectively; (5) the distribution of nuclear angle deviation for each cell type was generated with GraphPad Prism.

Nuclear Staining and Cell Density Analysis {#S2.SS6}
------------------------------------------

Cryosections of Y-TSPC (*n* = 4 donors) and A-TSPC (*n* = 6 donors) sheets (1 sheet/donor) were rehydrated in water for 5 min, then stained with 4′,6-diamidino-2-phenylindole (DAPI; 1:10 × 10^3^ dilution in H2O) for 5 min at room temperature (RT) and fluoroprotected with Mowiol 4-88 (Roth, Karlsruhe, Germany). Fluorescent images were acquired at 20x magnification with an Olympus XC10 camera on an Olympus BX61 fluorescence microscope (Olympus, Japan). In brief, (1) 9 randomly taken DAPI images/sheet were analyzed with ImageJ (v1.45s software National Institutes of Health, Bethesda, MD, United States)^[1](#footnote1){ref-type="fn"}^ software; (2) each image was converted into grayscale by using "threshold" adjustment tool; (3) total nuclear number and the nuclear aspect ratio (NAR) were quantified automatically with "analyze particles" tool; (4) the average cell (nuclei) density/sheet as well as per cell cohort was calculated and expressed per mm; (5) the frequency of different NAR for each cohort was generated with GraphPad Prism. Round cells are represented by NAR value close to 1, while flattened cells near to 0.

F-Actin Staining {#S2.SS7}
----------------

Cryosections of Y-TSPC (*n* = 4 donors) and A-TSPC (*n* = 6 donors) sheets (1 sheet/donor) were rehydrated in water for 5 min and permeabilizated with 0.2% Triton-X (Sigma-Aldrich) for 30 min at RT. Afterward, 1:200 phalloidin-AF488 in 1%BSA in PBS solution (Sigma-Aldrich) was applied for 60 min at RT. DAPI was used for nuclear counter-staining.

Resazurin Assay and DNA Quantification {#S2.SS8}
--------------------------------------

Resazurin assay was performed on the last day of the stimulation step according to the manufacturer's instructions (Sigma-Aldrich). Relative immunofluorescence was measured with fluorescent ELISA reader (TECAN, Zurich, Switzerland). Y-TSPC (*n* = 3 donors) and A-TSPC (*n* = 3 donors) 2D monolayers (3 dishes/donor) were evaluated.

Cell proliferation was estimated in 3D by DNA quantification of Y-TSPC (*n* = 3 donors) and A-TSPC (*n* = 3 donors) sheets (1 sheet/donor). All samples were digested with papain for 16 h at 60°C. Next, the DNA content was quantified by using a PicoGreen DNA kit (Invitrogen, Carlsbad, CA, United States) following the manufacturer's instructions. A standard curve based on known DNA concentration was applied to determine the total DNA content of the samples. Relative immunofluorescence was measured with TECAN.

TUNEL (Terminal Deoxynucleotidyl Transferase dUTP Nick end Labeling) Staining and Quantification {#S2.SS9}
------------------------------------------------------------------------------------------------

Cell apoptosis was detected by TUNEL staining of Y-TSPC (*n* = 4 donors) and A-TSPC (*n* = 6 donors) sheets (one sheet/donor). Samples were treated with 0.2% hyaluronidase (Sigma-Aldrich) for 1 h, and then permeabilized with 0.2% Triton-X. TUNEL reaction was carried out at 37°C for 1 h. Afterward, DAPI counterstaining (1:10 × 10^3^ dilution in H~2~O) was applied and the samples were mounted for imaging. 10 μl DNase in 70 μl RNA free buffer (Qiagen, Hilden, Germany) was applied. DNA-treated samples were used as a positive control. Apoptotic cell number was measured as follow: (1) 6 images/sheet were randomly taken at x20 magnification; (2) all images were analyzed by ImageJ software; (3) apoptotic cells were counted manually and average number per donor and per cohort were expressed per mm^2^.

RNA Isolation, cDNA Synthesis and Real Time Polymerase Chain Reaction (PCR) {#S2.SS10}
---------------------------------------------------------------------------

Y-TSPC (*n* = 3 donors) and A-TSPC (*n* = 3 donors) sheets (1 sheet/donor) were snap frozen ad cryocrushed, then used for total RNA extraction with Qiagen RNeasy Mini kit (Qiagen) following the manufacturer's instructions. For cDNA synthesis, 0.5 μg total RNA/sample and Transcriptor First-Strand cDNA Synthesis Kit (Roche, Mannheim, Germany) were used. Custom-designed Real-Time PCR plates with 48 different genes ([Table 1](#T1){ref-type="table"}) in format of 96-well/32+ by Bio-Rad (Bio-Rad Laboratories, Hercules, CA, United States) were implemented according to the manufacturer's instructions and our previously described protocols ([@B50]). Gene expression differences were calculated with the ΔΔCT method and presented as fold change of A-TSPC group to Y-TSPC group (control). Hypoxanthine-guanine phosphoribosyltransferase 1 gene (HPRT1), low abundant but also very stable, was implemented as housekeeper in calculating ΔCT. The CT values of HPRT1 were also used as indicative of gene abundance. The average CT value of HPRT1 was 27 (*n* = 6). From the 48 target genes, 38 genes had CT values lower than HPRT1. Threshold of HPRT1 Ct (27) + 3 Ct ≥ 30 Ct was set and genes with Ct ≥ 30 were considered not detectable or very low abundant, and therefore without fold change calculation. For cell senescence analysis, Real Time PCR for p16, p21, and p53 genes ([Table 2](#T2){ref-type="table"}) was performed as described by [@B23].

###### 

Genes included in Real Time PCR Ready Custom Designed Plates analyzed in this study.

  **Target gene**                                     **Abbreviation**   **Category**
  --------------------------------------------------- ------------------ -----------------------------
  Early growth response 1                             EGR-1              Tendon transcription factor
  Early growth response 2                             EGR-2              Tendon transcription factor
  Eyes absent homolog 1                               EYA1               Tendon transcription factor
  Eyes absent homolog 2                               EYA2               Tendon transcription factor
  Mohawk homeobox                                     MKX                Tendon transcription factor
  Scleraxis homolog A                                 SCXA               Tendon transcription factor
  SIX homeobox1                                       SIX1               Tendon transcription factor
  SIX homeobox2                                       SIX2               Tendon transcription factor
  Collagen, type I, alpha 1                           COL1A1             Collagen gene
  Collagen, type III, alpha 1                         COL3A1             Collagen gene
  Collagen, type V, alpha 1                           COL5A1             Collagen gene
  Collagen, type VI, alpha 1                          COL6A1             Collagen gene
  Collagen, type XII, alpha 1                         COL12A1            Collagen gene
  Collagen, type XIV, alpha 1                         COL14A1            Collagen gene
  Collagen, type XV, alpha 1                          COL15A1            Collagen gene
  Asporin                                             ASPN               Collagen cross-linker gene
  Lysyl oxidase                                       LOX                Collagen cross-linker gene
  Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1   PLOD1, LH1         Collagen cross-linker gene
  Biglycan                                            BGN                Tendon-related matrix gene
  Decorin                                             DCN                Tendon-related matrix gene
  Ephrin type-A receptor 4                            EPHA4              Tendon-related matrix gene
  Fibromodulin                                        FMOD               Tendon-related matrix gene
  Fibronectin 1                                       FN1                Tendon-related matrix gene
  Lumican                                             LUM                Tendon-related matrix gene
  Proteoglycan 4                                      PRG4               Tendon-related matrix gene
  Tenascin C                                          TNC                Tendon-related matrix gene
  Thrombospondin 2                                    THBS2              Tendon-related matrix gene
  Thrombospondin 4                                    THBS4              Tendon-related matrix gene
  Tenomodulin                                         TNMD               Tendon-related matrix gene
  Aggrecan                                            ACAN               Other lineage gene
  Collagen, type II, alpha 1                          COL2A1             Other lineage gene
  Alpha-actin-2                                       ACTA2,**α**-SMA    Other lineage gene
  Cartilage oligomeric matrix protein                 COMP               Other lineage gene
  Desmin                                              DES                Other lineage gene
  Integrin-binding sialoprotein                       IBSP               Other lineage gene
  Fucosyltransferase 4                                FUT4               Other lineage gene
  Lipoprotein lipase                                  LPL                Other lineage gene
  Myogenic differentiation 1                          MYOD1              Other lineage gene
  Myogenin                                            MYOG               Other lineage gene
  Nanog homebox pseudogene 8                          NANOG              Other lineage gene
  Octamer-binding transcription factor 4              Oct4, Pou5f1       Other lineage gene
  Peroxisome proliferator-activated receptor gamma    PPARG              Other lineage gene
  Runt-related transcription factor 2                 RUNX2              Other lineage gene
  Transcription factor Sp7                            SP7, Osterix       Other lineage gene
  SRY (sex-determining region Y)-box 9                SOX9               Other lineage gene
  Transcription factor AP-2 alpha                     TFAP2A             Other lineage gene
  Transforming growth factor beta 1                   TGF-β1             Other lineage gene
  Transglutaminase 2                                  TGM2               Other lineage gene
  Beta-2-Microglobulin                                B2M                Reference gene
  Glyceraldehyde 3-phosphate dehydrogenase            GAPDH              Reference gene
  Hypoxanthine-guanine phosphoribosyltransferase 1    HPRT1              Reference gene

###### 

PCR for senescence-related genes p16, p21, p53.

  **Target gene**   **Primers**                      **Annealing temperature \[°C\]**   **Cycle number**   **References**
  ----------------- -------------------------------- ---------------------------------- ------------------ ----------------
  p16               F 5′-caacgcaccgaatagttacg-3′     57                                 35                 [@B25]
                    R 5′-agcaccaccagcgtgtc-3′                                                              
  p21               F 5′-gaacttcgactttgtcaccgag-3′   60                                 30                 [@B1]
                    R 5′-cgttttcgaccctgagagtctc-3′                                                         
  p53               F 5′-aaggaaatttgcgtgtggag-3′     58                                 35                 [@B12]
                    R 5′-ttctgacgcacacctattgc-3′                                                           

Collagen I Immunofluorescent Staining and Enzyme-Linked Immunosorbent Assay (ELISA) {#S2.SS11}
-----------------------------------------------------------------------------------

Cryosections of Y-TSPC (*n* = 4 donors) and 6 A-TSPC (*n* = 6 donors) sheets (1 sheet/donor) were treated for antigen retrieval with 1% pepsin for 15 min at RT blocked by 1% bovine serum albumin (BSA) for 1 h, and incubated with primary anti-collagen type I antibody (Sigma-Aldrich, Cat. Nr. C2456, 1:200 dilution) overnight at 4°C. Next day, anti-mouse FITC secondary antibody (Sigma-Aldrich) was applied for 1h at RT, and last DAPI counterstaining was done for 5 min. Fluorescent images were acquired with an Olympus XC10 camera on an Olympus BX61 fluorescence microscope. The amount of deposited collagen I protein was detected by ELISA. 3 Y-TSPC and 5 A-TSPC donors analyzed (1 sheet/donor). First, total protein was extracted with 10 μg/ml pepsin and 1 mg/mL elastase. Next, collagen I Elisa kit (Chondrex, Redmond, WA, United States) was used according to the manufacturer's instruction. The data was expressed as total collagen I content/DNA.

Transmission Electron Microscopy (TEM) {#S2.SS12}
--------------------------------------

Transmission electron microscopy was applied to detect the ultrastructure of Y-TSPC (*n* = 3 donors) and A-TSPC (*n* = 5 donors) cell sheets. One cell sheet per donor was prepared for TEM analyses. After rinsing with PBS, samples were fixed with Karnovsky-fixatives (0.1M cacodylate-buffer with 2.5% glutaraldehyde and 2% paraformaldehyde), then enclosed within 4% low melting agarose, post-fixed with 1% osmium tetroxide at pH 7.3, dehydrated in graded ethanol, embedded in EMbed-812 epoxy resin (Science Services, Munich, Germany) and finally polymerized for 48 h at 60°C into an EPON block. Each cell sheet was halved and embedded for longitudinal or cross-sectional cutting. Semithin sections from 0.75 μm thickness were cut and stained with toluidine blue and basic fuchsine. After selection of appropriate areas of interest, the EPON block was trimmed and ultrathin sections (80 nm thickness) were cut on Reichert Ultracut-S ultramicrotome (Leica, Bensheim, Germany). Sections were mounted on grids and stained with aqueous 2% uranyl acetate and lead citrate solution for 10 min each. Next, the sections were examined with a LEO912AB electron microscope (Zeiss, Oberkochen, Germany) operating at 100 kV. Images were taken with a side-mounted 2k x 2k-CCD-camera (TRS, Moorenweis, Germany). The number of elongated cells and apoptotic cells (images of 80 × 80 μm^2^), as well as the diameter of the collagen fibers (images of 4 × 4 μm^2^) were evaluated as follows: (1) 6 images/donor were implemented; (2) all images were analyzed by ImageJ; (3) each image was converted to grayscale by using "threshold" adjustment; (4) the number of elongated cells, apoptotic cells and collagen fibrils were counted manually and the data was expressed as the mean of counted objects per image area per donor; (5) the diameter of collagen fibrils was measured by "straight" tool manually as 20 randomly chosen fibrils per image were assessed (6 images/donor; 120 fibrils/donor; 360 fibrils for Y-TSPC group and 600 fibrils for A-TSPC group were analyzed); (6) the collagen diameter distribution per group was expressed by calculating the frequency of fibrils with different diameters (total of 360 fibrils for Y-TSPC group and total of 600 fibrils for A-TSPC group). In [Figures 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"} representative images of Y-TSPC (*n* = 3 donors) and A-TSCP *n* = 5 (donors) are shown. GraphPad Prism v.5 software was used for quantitative data analyses and graphical data expression.

Statistics {#S2.SS13}
----------

GraphPad Prism v.5 software was used for expressing quantitative data and estimation of statistical significance. Unless distribution and frequency data, all data shows individual donors (dot plot) and mean values and standard deviations for each cohort. Statistical testing was performed with unpaired *t*-test. Difference were considered statistically significant when ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, and ^∗∗∗^*p* \< 0.001.

Results {#S3}
=======

A-TSPC Showed Inferior Sheets Formation With Higher Failure Rate {#S3.SS1}
----------------------------------------------------------------

In the first expansion step, A-TSPCs needed 2 more days to reach full cell confluence than Y-TSPCs. In the stimulation step, Y-TSPCs took 14 days to form a cell sheet, whilst A-TSPCs required 16.5 days ([Figure 1A](#F1){ref-type="fig"}). The gross appearances of sheets from both cell types were evaluated and compared ([Figure 1B](#F1){ref-type="fig"}), showing that A-TSPC sheets were much thinner and smaller than Y-TSPC sheets. Then, as mentioned in the Materials and Methods, 4 Y-TSPC donors and 9 A-TSPC donors were used in the study, and the total success rate for Y-TSPC sheet formation was 96.5% with only 1 failed sheet from Y3-TSPC donor (ruptured) because of the over stretching when handled. In contrast, for the A-TSPC group the overall success rate of sheet formation was only 61.1% and certain donors namely A1-, A3-, and A5-TSPC being unable to form any sheet ([Figure 1C](#F1){ref-type="fig"}). Next, cell sheet diameter and wet weight at day 1 and 14 were measured confirming that A-TSPC sheets were significantly smaller and lighter than Y-TSPC sheets at both the time points ([Figures 1D,E](#F1){ref-type="fig"}).

A-TSPC Sheets Had Lower Cell Density, Disorganized Matrix and Poor Cell Alignment {#S3.SS2}
---------------------------------------------------------------------------------

The general tissue morphology of the cell sheets was revealed by H&E staining ([Figure 2A](#F2){ref-type="fig"}) and analysis of the angle of nuclear deviation ([Figure 2B](#F2){ref-type="fig"}). A-TSPC cells formed an inferior cell sheet with less matrix deposition and frequent gaps. Y-TSPC formed bigger cell sheet containing a large amount of aligned fibrous matrix with higher number of spindle-like shaped cells. In addition, the cells in the A-TSPC sheets were sparser and rounded compared to the Y-TSPC group. Cell orientation was assessed by estimating the angular deviation of the cell nuclei to the axial axis of the cell sheet. The results showed that in the Y-TSPC group, over 60% of the nuclei deviated 0° to 20° from the axial axis, and the average nuclear angle was 15.69°. In contrast, in the A-TSPC group, less than 30% of the nuclei deviated from 0° to 20°, and the average nuclear deviation was nearly twofold increased to 29.95°. Next, the cell density and frequency distribution of the nuclei aspect ratio, which represents the nuclei flattening, were quantified ([Figures 2C--E](#F2){ref-type="fig"}) and revealed a significantly lower cell density in the aged group. Moreover, A-TSPC sheets contained significantly higher frequency of cells with NAR 0.8-0.9 corresponding to roundish cells. Analyses of the cell cytoskeleton via phalloidin fluorescent staining confirmed worse cell elongation and cytoskeletal organization in the A-TSPC group than the Y-TSPC group ([Figure 2F](#F2){ref-type="fig"}).

![Y-TSPC and A-TSPC histomorphometrical analyses. **(A)** Representative H&E images of Y-TSPC and A-TSPC sheets at day 14. **(B)** Frequency distribution of nuclear angle deviation (left panel) as well as maximum and average values of angular deviation (right panel, virtual angle between cell sheet longitudinal axis and nuclear axis). The arrow indicates the higher frequency of nuclear deviation of 10°--20° deviation in the Y-TSPC sheets. **(C)** Representative images of nuclear staining via DAPI (blue color) of Y-TPSC and A-TPSC sheets. **(D)** Average cell density of both groups. **(E)** Frequency distribution of NAR (nuclear aspect ratio, nucleus width versus length). The arrow indicates the higher tendency of NAR 0.8-1 (round cells) in A-TSPC group. (F) Representative F-actin images of Y-TSPC and A-TSPC sheets at day 14. Y-TSPC *n* = 4; A-TSPC *n* = 6; \**p* \< 0.05\*.](fbioe-08-00406-g002){#F2}

A-TSPC Sheets Showed Reduced Metabolic and Proliferative Activities, Whilst Augmented Apoptosis, Senescence {#S3.SS3}
-----------------------------------------------------------------------------------------------------------

For cell proliferation, Resazurin assay was carried out at the 2D cell monolayer level prior to sheet formation (day 18.5 for Y-TSPCs and day 22.5 for A-TSPC), followed by DNA content quantification. DNA was also quantified at the 3D cell sheet level at day 1 and day 14 ([Figures 3A--C](#F3){ref-type="fig"}). The results showed that A-TSPC group contained significantly lower cell amount than Y-TSPC group, paralleled by significantly higher metabolic cell activity, in the 2D step. At the 3D level, the data suggested that after the collection of the cell sheets in the A-TSPC group there is further cell loss. In contrast, in the period day 1 to day 14 at the 3D level cell proliferation occurred in the Y-TSPC sheets as indicated by an increase in DNA content. Furthermore, TUNEL staining of Y-TSPC and A-TSPC cell sheets revealed that A-TSPC sheets have significantly more apoptotic cells than Y-TSPC sheets ([Figures 3D,E](#F3){ref-type="fig"}). Cell senescence analysis was performed by quantitative PCR for the expression of cell cycle regulator genes p16, p21, and p53 and it demonstrated a significant upregulation of p16 and p21 in the A-TSPC sheet group ([Figure 3F](#F3){ref-type="fig"}).

![Quantitative analyses of cell proliferation, apoptosis and senescence. **(A,B)** Resazurin assay and DNA quantification at 2D prior sheet collection. **(C)** DNA quantification at 3D day 1 and day 14. **(D)** Representative TUNEL/DAPI images at 3D day 14. Apoptotic cells appear in green. Positive control with DNase treated. Negative control with label solution only (without terminal transferase). **(E)** Quantification of average apoptotic cell number in the sheets at day 14. **(F)** Quantitative PCR analysis of p16, p21, and p53. Y-TSPC *n* = 4; A-TSPC *n* = 6; \**p* \< 0.05 and \*\*\**p* \< 0.001. For PCR, Y-TSPC *n* = 3; A-TSPC *n* = 3.](fbioe-08-00406-g003){#F3}

A-TSPC Sheets Exhibited a Profound Phenotype at the Ultrastructural Level {#S3.SS4}
-------------------------------------------------------------------------

The ultrastructure of Y-TSPC and A-TSPC sheets was revealed by TEM. In Y-TSPC sheets, cells appeared elongated and in many locations organized in parallel rows compared to A-TSPC sheets ([Figures 4a--l](#F4){ref-type="fig"}). In addition, Y-TSPC sheets had higher cellular density ([Figures 4a--c](#F4){ref-type="fig"}); the ECM was rich in collagen type I fibrils that were densely packed ([Figures 5a--c](#F5){ref-type="fig"}). In contrast, A-TSPCs exhibited a rounded morphology within the sheets as well as their ECM was less dense and contained few sparsely distributed collagen fibrils ([Figures 4g--l](#F4){ref-type="fig"}, [5g--i](#F5){ref-type="fig"}). In the Y-TSPC sheets, plasmalemma vesicles at the cell membrane ([Figure 5d](#F5){ref-type="fig"}) as well as cell protrusions ([Figures 4d--f](#F4){ref-type="fig"}) and cell-cell contacts ([Figure 5e](#F5){ref-type="fig"}) were frequently detected. They were also visible in A-TSPC sheets but very rarely ([Figures 4j--l](#F4){ref-type="fig"}, [5j,k](#F5){ref-type="fig"}). Interestingly, A-TSPC sheets contained multiple apoptotic bodies indicative of cells that undergo programmed cell death ([Figures 4g--i](#F4){ref-type="fig"}, [5l](#F5){ref-type="fig"}). Apoptotic cells were rare in sheets formed by Y-TSPCs ([Figures 4a--c](#F4){ref-type="fig"}, [5f](#F5){ref-type="fig"}). However, both types of cells however were comparable regarding vacuoles and mitochondria ([Figures 4d--f,j--l](#F4){ref-type="fig"}, [5d,e,j,k](#F5){ref-type="fig"}). Next, quantification analysis of TEM image data confirmed the above observation and clearly showed that A-TSPC sheets had a significantly reduced number of elongated cells and collagen fibrils, but significantly increased number of apoptotic cells ([Figures 6A,B,D](#F6){ref-type="fig"}). Regarding collagen fibril diameter distribution, both types of cell sheet were comparable with fibril diameter spanning 10--50 nm ([Figure 6C](#F6){ref-type="fig"}). In all, the TEM analyses strongly confirmed the profound phenotype of the A-TSPC sheet at the ultrastructural level.

![Representative transmission electron microscopy (TEM) images of Y-TSPC and A-TSPC sheets. **(a--c)** Y-TSPC sheet cell arrangement, cell density and morphology. **(d--f)** Close view of Y-TSPC morphology and cell protrusions. **(g--i)** A-TSPC sheet cell arrangement, cell density and morphology. **(j--l)** Close view of A-TSPC morphology and cell protrusions. Black arrows, apoptotic cells; green arrows, cell protrusions; red arrows, cell--cell contact; m, mitochondria; n, nucleus; v, vacuoles; \*, longitudinal cell; Y-TSPC *n* = 3, A-TSPC *n* = 5 were investigated.](fbioe-08-00406-g004){#F4}

![Representative transmission electron microscopy (TEM) images of Y-TSPC and A-TSPC sheets. **(a--c)** Y-TSPC sheet collagen fibrils. **(d)** Y-TSPC sheet plasmalemma vesicles at the cell membrane. **(e)** Y-TSPC sheet cell-to-cell contacts between cells. **(f)** Y-TSPC sheet close view of apoptotic bodies. **(g--i)** A-TSPC sheet collagen fibrils. **(j)** A-TSPC sheet plasmalemma vesicles at the cell membrane. **(k)** A-TSPC sheet cell-to-cell contacts between cells. **(l)** A-TSPC sheet close view of apoptotic bodies. Arrow head, collagen fibrils; black arrows, apoptotic cells, brown arrows, plasmalemma vesicles; red arrows, cell--cell contact; m, mitochondria; n, nucleus; v, vacuoles; Y-TSPC *n* = 3, A-TSPC *n* = 5 were investigated.](fbioe-08-00406-g005){#F5}

![Quantification of elongated cells **(A)**, collagen fibrils and diameter distribution **(B,C)** and apoptotic cell numbers **(D)** from TEM images. Y-TSPC *n* = 3; A-TSPC *n* = 5; for **(A,B,D)**, 6 images/donor were analyzed; for **(C)** 20 randomly chosen fibrils per image were assessed; \**p* \< 0.05.](fbioe-08-00406-g006){#F6}

A-TSPC Sheets Contained Lower Collagen I Protein {#S3.SS5}
------------------------------------------------

In addition, to the TEM analysis, collagen type one deposition was further validated by conducting collagen I immunofluorescence staining and ELISA ([Figures 7A,B](#F7){ref-type="fig"}). Our results clearly demonstrated that A-TSPC sheets had significantly lower collagen I protein content than Y-TSPC sheets.

![Collagen I protein production and gene expression profiling by Real Time PCR. **(A)** Representative collagen I immunofluorescent images of Y-TSPC and A-TSPC sheets at day 14. **(B)** Quantitative analysis of collagen I by ELISA. For **(A,B)** Y-TSPC *n* = 3; A-TSPC *n* = 6. Normalization to DNA. Quantitative PCR analysis for tendon-transcription factors **(C)**, collagen genes **(D)**, cross-linker genes **(E)**, tendon-related ECM genes **(F)** other lineage genes **(G)**. Gene expression was calculated as fold change to Y-TSPC group. GAPDH was used as reference gene in each group. Non-detectable (Ct over 38 genes were not included in the graphs. For **(C--G)** Y-TSPC *n* = 3; A-TSPC *n* = 3; ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, and ^∗∗∗^*p* \< 0.001.](fbioe-08-00406-g007){#F7}

A-TSPC Sheets Displayed Abnormal Gene Expression Profile {#S3.SS6}
--------------------------------------------------------

Real-time PCR for 48 different genes ([Table 1](#T1){ref-type="table"}) was carried out with mRNA/cDNA collected from Y-TSPC and A-TSPC sheets at day 14. Gene markers for other lineages, namely for cartilage - collagen 2a1 (COL2A1) (cartilage); for muscle -- desmin (DES), myogenic differentiation 1 (MYOD1) and myogenin (MYOG); for bone -- Sp7 (SP7, Osterix) and integrin-binding sialoprotein (IBSP); for fat -- AP-2 alpha (TFAP2A) and lipoprotein lipase (LPL); and for embryonic lineage -- Nanog homebox pseudogene 8 (NANOG) were not detectable. Several genes that are tendon-related -- early growth response protein 2 (EGR2), eyes absent homolog 1 (EYA1), transglutaminase 2 (TGM2) and tenomodulin (TNMD) were also not detectable or very low abundant. The mRNA levels of tendon transcription factors ([Figure 7C](#F7){ref-type="fig"}) were comparable between the two groups. Several collagen genes namely collagen 1a1 (COL1A1), collagen 3a1 (COL3A1), collagen 5a1 (COL5A1), collagen 6a1 (COL6A1), collagen 15a1 (COL15A1), had significantly lower expression in the A-TSPC sheets ([Figure 7D](#F7){ref-type="fig"}). In addition, a gene related to collagen cross-linking such as procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1) and the matrix proteoglycans decorin (DCN), fibromodulin (FMOD), fibronection (FN), tenascin C (TNC) and thrombospondin 2 were also significantly downregulated in the A-TSPC sheets ([Figures 7E,F](#F7){ref-type="fig"}). Regarding other lineage related genes, three genes aggrecan (ACAN), alpha-actin 2 (ACTA2), cartilage oligomeric matrix protein (COMP) were also found to be expressed to a lower extent in the A-TSPC group ([Figure 7G](#F7){ref-type="fig"}). Altogether, this data demonstrated a fundamental matrix synthesis problem in the A-TSPC sheets.

Discussion {#S4}
==========

Tendon injuries, which associate closely with aged-related tissue degeneration present great challenges to orthopedic and trauma surgery departments. Aged-related tissue degeneration has been previously linked to impaired functions of tissue-resident stem/progenitor cells ([@B39]; [@B33]; [@B2]). Han et al. suggested that with donor aging smooth muscle-derived MSCs have greatly diminished self-renewal and proliferation abilities but augmented senescence ([@B15]). In order to investigate how aging affects TSPCs, we compared the phenotypic difference between Achilles tendon-derived Y-TSPC from young/healthy and A-TSPC from aged/degenerative human donors. Our previous data in 2D culture, revealed that A-TSPC had a significantly reduced cell adhesion, migration and self-renewal abilities with distinct clonogenic deficits and premature entry into senescence ([@B23]), suggesting that the TSPC pool is becoming exhausted in terms of size and functional fitness during tendon age-related degeneration.

Here, we applied a previously established cell sheet model ([@B20]) for *in vitro* tenogenesis and compared the sheet formation of Y-TSPCs and A-TSPCs with the purpose of unraveling differences in their potential to form 3D tendon organoids. Formation of cell sheets is an alternative scaffold-free approach to build an abundant ECM niche without elimination of the native connections between cells to cells and cells to ECM. Furthermore, the cell multilayer contains a natural microenvironment and maintains its own autocrine and paracrine signaling ([@B20]). Several growth factors such as members of the Transforming Growth Factor beta family, TGF-β1, β2, and β3, have been reported to be critical for tendon tissue formation, function and healing ([@B31]; [@B27]; [@B18]; [@B44]). Connective Tissue Growth Factor (CTGF) has also been linked to tenogenesis; for example, it is pro-tenogenic factor of adipose-derived stem cells ([@B38]; [@B26]). Interestingly, [@B52] have combined CTGF and TGF-β1 in a step-wise manner, which led to augmented tenogenic differentiation of MSCs, as well as to tendon-like tissue formation in the repair process of rat patella tendon defect. CTGF alone or in combination with TGF-β has also been associated with fibrocartilage formation in meniscal injury models ([@B24]; [@B45]). Therefore, as well as to minimize costs, we designed our study with administration of only one growth factor from the TGFβ family. However, it will be of great importance in follow up research to investigate the synergistic action of CTGF and TGFβ in the 3D tendon cell sheet model, which may result in quicker maturation of the cell sheets.

In the present study, our results clearly showed that A-TSPCs exhibit profound deficits in forming 3D tendon tissue organoids. There are several possible explanations: A-TSPC sheets have (1) reduced cell proliferation; (2) augmented cell apoptosis and senescence; and (3) less ECM production.

Tissue and organ aging has a strong relationship with stem cell proliferation ability, apoptosis and senescence. [@B21] reported that the size of MSCs pool reduces in aged animals, compared to young animals. [@B53] demonstrated that aged rhesus macaque BMSCs require longer population doubling time due to decreased proliferation capacity. In our study, cell proliferation was tested prior to sheet collection and at day 1 and 14, revealing that A-TSPC sheets have significantly lower cell density and proliferation rate than Y-TSPC sheets. [@B22] communicated that progeroid mice contained higher numbers of apoptotic muscle stem/progenitor cells. [@B46] showed that in human colonic crypts, age-related DNA mutations are associated with stem cell apoptosis. By performing TUNEL assays for DNA damage, we observed that the A-TSPC sheets also contain more apoptotic cells than the Y-TSPC group. Furthermore, we found that senescence-related gene markers namely p16 and p21 ([@B5]) were significantly upregulated in the A-TSPC group, This finding is in line with skeletal muscle aging, where local stem cells undergo a dysregulation in p16 signaling that is directly related to an augmentation in muscle tissue senescence. Interestingly, reducing p16 expression might be a way to postpone tissue and organ aging ([@B3]). Silencing of p16 expression can reduce the number of senescent cells thus restoring the regenerative potential of muscle tissue, which was shown by [@B40]. In all, the above results indicated that A-TSPC 3D sheets, characterized with a lower cell density and proliferation potential, whilst having higher cell apoptosis and senescence, are significantly inferior then Y-TSPC sheets.

Tendon ECM is very fibrous and organized in parallel collagen fibers. Roughly 95% of the collagen is type I, with small levels of collagen types III, V, VI, XII, XIV, and XV. The non-collageneous proteins in the tendon ECM belong to proteoglycan and glycoprotein family and smaller amount of proteoglycans (e.g., decorin, biglycan, fibromodulin, lumican) such glycoproteins (e.g., COMP, TNC, PRG4. TNMD) ([@B11]; [@B37]). In the current study, we could not detect TNMD gene expression in neither of the TSPC groups, most likely due to transcript loss in the cell expansion step. Rapid downregulation of TNMD mRNA in 2D and 3D cultured human TSPCs was previously described ([@B10]). The ECM provides a natural physical microenvironment for cellular connections and also regulates cellular processes such as proliferation and differentiation ([@B47]). Aged stem cells still possess multipotency and are capable of ECM deposition ([@B42]; [@B53]). However, it has been reported that cell aging can lead to a reduction in COL content ([@B16]; [@B7]). In our study, we found that A-TSPC sheets contained significantly less ECM with poor alignment when compared to the Y-TSPC sheets. Connor et al. (2019) showed that senescent fibroblast has downregulated COL1A1 and elastin gene expression, compared to young fibroblast. This is comparable to our study revealing in A-TSPC sheets had a significant lower COL1 expression at mRNA and protein levels. COL 3 and COL 5, fibrillar collagens expressed in the human tendon tissue, that are important for the optimal fibrillary formation and tissue quality ([@B21]) were both also significantly downregulated in the A-TSPC group. Our results are in line with two omics studies. Proteomic analysis of engineered tendon constructs by young or aged equine tenocytes revealed that tendon aging was associated with altered ECM protein, and especially COL type I, III and IV as well as proteins involved in cell-matrix interaction and mechanotransduction such as calponin 1, paladin, caldesmon 1 and contracting ([@B48]). Moreover, the data suggested a lower cytoskeleton turnover in the aged group ([@B48]), confirming independently the findings in [@B23]. Transcriptome comparison of uninjured human Achilles tendon tissue biopsies from young and old patients demonstrated with tendon age a differential expression of genes related to cellular function, growth and the cell cycle ([@B29]). Interestingly, downregulation of COL transcripts and genes involved in the post translational modification of COL were also affected ([@B29]). A gene called SPARC (secreted protein acidic and rich in cysteine) has been shown to play an important role in ECM assembly and particularly in dermal fibroblast to regulate processing of procollagen I and COL fibrilogenesis ([@B34]; [@B4]). Interestingly, tendon tissues from Sparc-deficient mice, also exhibited altered actin cytoskeleton as well as collagen fibrilogenesis defects ([@B13]) and hence, will be relevant to assess in the future, SPARC expression levels in the A-TSPC sheets. On the contrary, the study by [@B8] suggested that the COL fibril numbers remain unchanged during aging in both animal and human tendon tissue, but the enzymatic or non-enzymatic cross-linkers of the fibrils, thereby their size, can be affected during aging ([@B43]). We analyzed other genes related to COL fibril regulation such as proteoglycans (DCN, FMOD, FN1, TNC, THBS2, COMP) and PLOD1, and found several being significantly downregulated in the A-TSPC group. These novel molecular candidates can be the foundation in follow up studies to investigate molecular cascades in both directions -- up and downstream in order to elucidate the molecular mechanisms leading to the deficiency in matrix synthesis by A-TSPCs. Altogether, this data indicates the A-TSPC group harbors significant ECM production deficit.

With aging some structural changes of the COL fibrils occur; as mentioned above, changes in their size, but also shape and even biomechanical properties ([@B32]). We carried out TEM and investigated COL fibril diameter size but found no significant differences between the groups. One possibility is that during *in vitro* culture without dynamic mechanical loading the lateral growth of the COL fibril size is limited. In future, it will be of interest to subject both type of sheets to periodic axial stretching, as well as to examine their biomechanical properties, for example by the means of Force Indentation Atomic Force Microscopy. Nevertheless, the TEM analyses independently validated that A-TSPC contained less and disorganized cells exhibiting round and apoptotic morphologies embedded in a very poor COL matrix. The structural and biomechanical properties of the ECM can profoundly affect cell behavior. Interestingly, providing A-TSPCs with hydrogel environment consisting of aligned nanonfibers alleviated their aged phenotype ([@B51]). Hence, "engineering a healthy" ECM niche might be an attractive way to rejuvenate aged cells, support their growth and direct their fate decision and differentiation.

Our study has several shortcomings that need to be addressed in follow up research: (1) Due to the manual rolling of the cell sheets, some ECM and cells are lost, therefore standardizing this process will be of importance; (2) A time point longer that 14 days can be evaluated to investigate if the A-TSPC sheets further deteriorate; (3) As mentioned above, subjecting the 3D tendon organoids to periodic axial stretching will be relevant to examine if this can lead to sheet diameter growth. In addition, efforts to speed up the sheet formation process and to become more economic, regarding required cell numbers will be very important.

Taken together, our study reports as in 2D culture, so in 3D culture A-TSPCs show cell autonomous deficits namely, significantly reduced renewability but significantly increased senescence and apoptosis. Furthermore, we report the following novel findings: (1) A-TSPCs have a severe issue with ECM production, which was validated at the mRNA and protein levels; (2) they are less competent to organize the ECM and to properly align in the third dimension; (3) Q-PCR profiling identified novel molecular candidates such as collagen genes (COL I, III, V, VI, and XV) and proteoglycans (DCN, FMOD, FN1, TNC, THBS2, COMP, PLOD1) which can help to elucidate the exact molecular circuits behind the deficiency in ECM synthesis. Further validation at the protein level as well as "gain" and "loss" of function experiments will be of great interest to follow. Last but not least, the 3D sheet model can become very attractive for (1) developing an effective 3D tenogenic differentiation protocol for wide use similarly to the well-known and accepted chondorgenic in pellet cultures and (2) for screening of small pharmacological cues for rejuvenation of the A-TSPC sheets and to evaluate side effects of available or in development medications on tendon tissues.

Data Availability Statement {#S5}
===========================

The datasets generated for this study are available on request to the corresponding author.

Ethics Statement {#S6}
================

The studies involving human participants were reviewed and approved by Ethics Committee of the Medical Faculty of the Ludwig-Maximilians-University, Munich (Ethical Grant No. 166-08). The patients/participants provided their written informed consent to participate in this study.

Author Contributions {#S7}
====================

DD conceived and designed the study, analyzed the data, and wrote the manuscript. ZY designed and performed the experiments, analyzed the data, and wrote the manuscript. HY analyzed the data and edited the manuscript. CB conducted TEM experiments. CP and VA provided the clinical expertise. All co-authors have read and approved the manuscript.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** DD acknowledges the financial support of the EU H2020-WIDESPREAD-05-2017-Twinning Grant "Achilles: Overcoming specific weakness in tendon biology to design advanced regenerative therapies" Proposal Nr. 810850. ZY is grateful for the support from the China Scholarship Council (CSC) (Grant No. 201708080098).

The authors thank Daniela Drenkard for valuable technical assistance, Heiko Siegmund for the TEM technical support, and Dr. Girish Pattappa for English proofreading.

<https://imagej.nih.gov/ij/>

Supplementary Material {#S10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fbioe.2020.00406/full#supplementary-material>

###### 

Click here for additional data file.

ACAN

:   aggrecan

ACTA2

:   alpha-actin 2

ADSC

:   adipose-derived stem cell

AR

:   aspect ratio

A-TSPC

:   aged tendon stem/progenitor cell

BMSC

:   bone mesenchymal stem cell

BSA

:   bovine serum albumin

CDKN2a

:   cyclin-dependent kinase Inhibitor 2a

COL

:   collagen

COMP

:   cartilage oligomeric matrix protein

DCN

:   decorin

DES

:   desmin

ELISA

:   enzyme-linked immunosorbent assay

ECM

:   extracellular matrix

FMOD

:   fibromodulin

FN

:   fibronectin

LPL

:   lipopretionlipase

NAR

:   nuclear aspect ratio

OSX

:   osterix

PBS

:   phosphate buffered saline

PLOD

:   procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1

RT

:   room temperature

TEM

:   transmission electron microscopy

TGFB1

:   transforming growth factor beta 1

THBS

:   thrombospondin

TNC

:   tenascin C

TUNEL

:   terminal deoxynucleotidyl transferase dUTP nick end labeling

Y-TSPC

:   young tendon stem/progenitor cell.
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